- $126.16m
- $125.99m
- $61.86m
Brief: Journey Medical Corporation Announces Positive Comparative Pharmacokinetic Data For Dfd-29
Journey Medical Corp reports results for the quarter ended in September - Earnings Summary
Journey Medical Corp expected to post a loss of 40 cents a share - Earnings Preview
Brief: Journey Medical Achieves 50% Enrollment In Phase 3 Trials Of Papulopustular Rosacea Treatment
Journey Medical Corp reports results for the quarter ended in June - Earnings Summary
Brief: Journey Medical Reports Q2 Loss Per Share $0.43
Brief: Entera Bio Announces Execution Of Key Regulatory Milestones For Eb613, The First Oral Anabolic Drug Proposed For The Treatment Of Osteoporosis Miranda Toledano Assumes CEO Position
Brief: Journey Medical Announces Settlement Agreements Pertaining To Qbrexza, Amzeeq And Zilxi Patent Exclusivity
Brief: Entera Bio Board Member, Miranda Toledano, To Assume Role Of Chief Business Officer, Chief Financial Officer, And Head Of Corporate Strategy
Brief: Journey Medical Corp Reports Full-Year 2021 Financial Results
Brief: Journey Medical Corporation Announces First Patient Dosed In Phase 3 Clinical Trial Evaluating Dfd-29 (Minocycline Modified Release Capsules 40 Mg) For The Treatment Of Rosacea
Vyne Therapeutics gains on sale of topical skin cream assets
Brief: Vyne Therapeutics Divests Topical Minocycline Assets
Brief: Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products And Molecule Stabilizing Technology Franchise From Vyne Therapeutics
Brief: Journey Medical Corporation Reports Q3 Loss Per Share of $1.16
Brief: Journey Medical Closes Initial Public Offering
Journey Medical trips in public debut
NASDAQ RESUMED AT 10:54 AM
Brief: Journey Medical Corp Prices $35.2 Mln Initial Public Offering